This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Evaluating the Duration of Efficacy of One Intra Articular Injection of Sodium Hyaluronate 2.0% in Patients With Painful Osteoarthritis of the Knee

This study has been completed.
Information provided by (Responsible Party):
TRB Chemedica Identifier:
First received: January 31, 2011
Last updated: November 20, 2012
Last verified: November 2012
A pilot, open, randomised, controlled, add-on study evaluating the duration of efficacy of one intra articular injection of sodium hyaluronate 2.0% in patients with painful osteoarthritis of the knee

Condition Intervention Phase
Osteoarthritis Patient Drug: Ostenil plus Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot, Open, Randomised, Controlled, add-on Study Evaluating the Duration of Efficacy of One Intra Articular Injection of Sodium Hyaluronate 2.0% in Patients With Painful Osteoarthritis of the Knee

Resource links provided by NLM:

Further study details as provided by TRB Chemedica:

Primary Outcome Measures:
  • to evaluate the duration of efficacy of one intra articular injection of Ostenil® Plus in patients with painful osteoarthritis of the knee. [ Time Frame: 6 months ]
    WOMAC score

Secondary Outcome Measures:
  • to evaluate the effects of the study treatment on pain, joint stiffness, joint function and need for analgesic consumption. [ Time Frame: 6 months ]

Enrollment: 20
Study Start Date: March 2011
Study Completion Date: July 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ostenil plus
Patient will get Ostenil plus injection and standard treatment of Osteoarthritis
Drug: Ostenil plus
2% Sodium Hyaluronate plus Mannitol injection


Ages Eligible for Study:   40 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients of both genders between 40 and 70 years of age;
  2. Primary tibiofemoral osteoarthritis of the knee according to American College of Rheumatology criteria;
  3. Pain ≥ 4 on a 10 point scale for at least two out of five subscores of the WOMAC Section A at baseline;
  4. Radiologically ascertained grade II or III severity knee osteoarthritis on the Kellgren-Lawrence scale;
  5. Having given signed informed consent.

Exclusion Criteria:

  1. Secondary knee osteoarthritis, including:

    • septic arthritis;
    • inflammatory joint disease;
    • gout;
    • recurrent episodes of pseudogout;
    • Paget's disease of bone;
    • articular fracture;
    • ochronosis;
    • acromegaly;
    • haemochromatosis;
    • Wilson's disease;
    • primary osteochondromatosis.
  2. Clinical signs of acute flare (pain, warm, erythema, effusion of signal knee) at baseline;
  3. Axial deviation > 15 degrees in valgus or varus on a standing X-ray;
  4. Clinically significant medio-lateral or antero-posterior instability;
  5. Rapid destructive arthritis, evolving arthritis requiring surgery within the coming year;
  6. Significant injury to the signal knee within 6 months prior to baseline;
  7. Complete loss of range of motion;
  8. Painful knee conditions other than osteoarthritis (e.g., Sudeck's atrophy, intra-articular neoplasm, villonodular synovitis);
  9. Necrosis of one of the femur condyles;
  10. History or evidence of gout, chondrocalcinosis;
  11. Peripheral neuropathy;
  12. Concomitant rheumatic disease:

    • fibromyalgia;
    • rheumatoid arthritis;
    • collagen diseases;
    • psoriatic arthritis and other seronegative spondylarthropathies (e.g., ankylosing spondylitis);
    • metabolic and crystal-induced arthropathies;
    • other osteopathies.
  13. Contraindications to intra-articular injection according to investigator's judgement (e.g., local infection at injection site, generalised infection with possible bacteraemia);
  14. Skin disease in the area of injection;
  15. Severe coagulopathy, ongoing anticoagulation therapy;
  16. Accompanying OA of the hip of sufficient severity to interfere with the assessment of the signal knee;
  17. Disease of spine, hip or other lower extremity joints of sufficient degree to affect assessment of the signal knee;
  18. Poor general health interfering with compliance or assessment;
  19. Concomitant disease/ailment other than knee OA requiring the regular use of the patient's normal analgesic medicine;
  20. Initiation of chronic treatment with antihistaminics, glucocorticoids, antidepressants or tranquilisers, within less than 3 months prior to baseline;
  21. Use of assistive devices other than a cane (walking stick);
  22. Surgery of the signal knee other than arthroscopy;
  23. Arthroscopy of the signal knee within one year prior to baseline;
  24. Treatment with symptomatic slow acting drug for OA (SYSADOA, i.e., chondroitin sulfate, diacerein, glucosamine, piascledine), unless the patient has been on a stable dose for at least 4 months prior to baseline;
  25. Intra-articular depocorticosteroid injection into the signal knee within 3 months prior to baseline;
  26. Intra-articular SH injection into the signal knee within 6 months prior to baseline;
  27. Ascertained hypersensitivity to any product used in the study (SH, paracetamol, diclofenac, omeprazole) or to similar compounds;
  28. Pregnant or lactating female;
  29. Female of childbearing potential without adequate contraceptive methods;
  30. Participation in a drug clinical trial within 3 months prior screening;
  31. Patients who, in the judgement of the investigator, will not comply with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01288001

Siriraj Hospital
Bangkoknoi, Bangkok, Thailand, 10700
Sponsors and Collaborators
TRB Chemedica
  More Information

Responsible Party: TRB Chemedica Identifier: NCT01288001     History of Changes
Other Study ID Numbers: OSTP-THA-10-01
Study First Received: January 31, 2011
Last Updated: November 20, 2012

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents processed this record on August 18, 2017